Literature DB >> 29332094

Low-Dose Oral Immunotherapy Using Low-Egg-Allergen Cookies for Severe Egg-Allergic Children Reduces Allergy Severity and Affects Allergen-Specific Antibodies in Serum.

Akihiro Maeta1, Marin Matsushima, Nozomi Muraki, Mariko Asano, Yuri Takaoka, Makoto Kameda, Kyoko Takahashi.   

Abstract

BACKGROUND: We evaluated the safety and efficacy of low-egg-allergen cookies (LAC) as low-dose oral immunotherapy (OIT) in children with severe egg allergy. We also examined the relationship between mild desensitization by low-dose OIT and serum biomarkers of allergy.
METHODS: We enrolled 13 children with egg allergy who could not receive OIT with hard-boiled egg white (EW). For 11 participants, OIT was carried out using LAC for 3-4 months. Open food challenges with hard-boiled EW and blood samplings were performed before and after OIT. Participants were divided into 2 groups: high effect (H-E) and no/low effect (N/L-E). Serum levels of total IgE and egg yolk-, EW-, and ovomucoid (OM)-specific IgE, ovalbumin (OVA)- and OM-specific IgG4, IgA1, and IgA2, and the percentage of CD 203c+ were measured.
RESULTS: Allergic severity was reduced in 7 patients, who were assigned to the H-E group. Moreover, no study participants were taken off the intake of LAC during OIT. In the H-E group, OVA-specific IgA2 levels after OIT were significantly higher than before OIT. The ratios of OM-specific IgG4/OM-specific IgE and OM-specific IgA2/OM-specific IgE in the H-E group after OIT were significantly higher than before OIT.
CONCLUSION: Our findings suggest that low-dose OIT using LAC is an effective and safe treatment for patients with severe egg allergy.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Allergen-specific immunotherapy; Egg allergy; Low-allergen cookies; Oral administration

Mesh:

Substances:

Year:  2018        PMID: 29332094     DOI: 10.1159/000485891

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  5 in total

1.  Co-delivery of allergen epitope fragments and R848 inhibits food allergy by inducing tolerogenic dendritic cells and regulatory T cells.

Authors:  Jingyi Hong; Xiaojun Xiao; Qichan Gao; Shanshan Li; Bei Jiang; Xizhuo Sun; Pixin Ran; Pingchang Yang
Journal:  Int J Nanomedicine       Date:  2019-08-30

Review 2.  Oral Immunotherapy (OIT): A Personalized Medicine.

Authors:  Francesca Mori; Simona Barni; Giulia Liccioli; Elio Novembre
Journal:  Medicina (Kaunas)       Date:  2019-10-13       Impact factor: 2.430

Review 3.  Immunological Outcomes of Allergen-Specific Immunotherapy in Food Allergy.

Authors:  Ann-Marie Malby Schoos; Dominique Bullens; Bo Lund Chawes; Joana Costa; Liselot De Vlieger; Audrey DunnGalvin; Michelle M Epstein; Johan Garssen; Christiane Hilger; Karen Knipping; Annette Kuehn; Dragan Mijakoski; Daniel Munblit; Nikita A Nekliudov; Cevdet Ozdemir; Karine Patient; Diego Peroni; Sasho Stoleski; Eva Stylianou; Mirjana Tukalj; Kitty Verhoeckx; Mihaela Zidarn; Willem van de Veen
Journal:  Front Immunol       Date:  2020-11-03       Impact factor: 7.561

Review 4.  The Road Toward Transformative Treatments for Food Allergy.

Authors:  Allyssa Phelps; Kelly Bruton; Emily Grydziuszko; Joshua F E Koenig; Manel Jordana
Journal:  Front Allergy       Date:  2022-02-09

5.  Early life exposure to house dust mite allergen prevents experimental allergic asthma requiring mitochondrial H2O2.

Authors:  Huijuan Yuan; Jie Chen; Sanmei Hu; Timothy B Oriss; Sagar Laxman Kale; Sudipta Das; Seyed M Nouraie; Prabir Ray; Anuradha Ray
Journal:  Mucosal Immunol       Date:  2021-09-27       Impact factor: 7.313

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.